Whereas the globally acting CB1R blocker rimonabant once held tremendous promise in ameliorating the metabolic abnormalities of obesity, its CNS-mediated adverse effects limited its clinical use. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.